Table 2.
Clinical parameters of patients with primary breast cancer tissue (PTT) and lymph node tissue (LNT) displaying low or high PTK7 expression (binary variable)
| PTK7 expression in PTT
|
PTK7 expression in LNT
|
|||||||
|---|---|---|---|---|---|---|---|---|
| Total | Low | High | P-value | Total | Low | High | P-value | |
| Age, years | 1.000 | |||||||
| ≤50 | 40 | 17 (42.5%) | 23 (57.5%) | 40 | 20 (50.0%) | 20 (50.0%) | ||
| >50 | 77 | 49 (63.6%) | 28 (36.4%) | 0.033 | 68 | 34 (50.0%) | 34 (50.0%) | |
| Tumor size | 0.640 | |||||||
| pT1 | 40 | 21 (52.5%) | 19 (47.5%) | 36 | 21 (58.3%) | 15 (41.7%) | ||
| pT2 | 59 | 34 (57.6%) | 25 (42.4%) | 56 | 26 (46.4%) | 30 (53.6%) | ||
| pT3 | 11 | 7 (63.6%) | 4 (36.4%) | 10 | 4 (40.0%) | 6 (60.00%) | ||
| pT4 | 7 | 4 (57.1%) | 3 (42.9%) | 0.915 | 6 | 3 (50.0%) | 3 (50.0%) | |
| Histological type | 0.360 | |||||||
| Invasive ductal | 96 | 51 (53.1%) | 45 (46.9%) | 90 | 44 (48.9%) | 46 (51.1%) | ||
| Invasive lobular | 15 | 11 (73.3%) | 4 (26.7%) | 12 | 8 (66.7%) | 4 (33.3%) | ||
| Other | 6 | 4 (66.7%) | 2 (33.3%) | 0.297 | 6 | 2 (33.3%) | 4 (66.7%) | |
| Lymph node status | <0.001 | |||||||
| N0 | 29 | 18 (62.1%) | 11 (37.9%) | 28 | 20 (71.4%) | 8 (28.6%) | ||
| N1 | 44 | 23 (52.3%) | 21 (47.7%) | 41 | 25 (61.0%) | 16 (39.0%) | ||
| N2 | 27 | 14 (51.9%) | 13 (48.1%) | 23 | 8 (34.8%) | 15 (65.2%) | ||
| N3 | 17 | 11 (64.7%) | 6 (35.3%) | 0.708 | 16 | 1 (6.2%) | 15 (93.8%) | |
| Estrogen receptor status | 0.067 | |||||||
| Positive | 90 | 52 (57.8%) | 38 (42.2%) | 83 | 46 (55.4%) | 37 (44.6%) | ||
| Negative | 27 | 14 (51.9%) | 13 (48.1%) | 0.660 | 25 | 8 (32.0%) | 17 (68.0%) | |
| Human epidermal growth factor receptor 2 | 0.058 | |||||||
| Negative | 92 | 56 (60.9%) | 36 (39.1%) | 83 | 46 (55.4%) | 37 (44.6%) | ||
| Positive | 23 | 10 (43.5%) | 13 (56.5%) | 0.160 | 23 | 7 (30.4%) | 16 (69.6%) | |
| Histological grading | 0.479 | |||||||
| G1 | 9 | 5 (55.6%) | 4 (44.4%) | 9 | 6 (66.7%) | 3 (33.3%) | ||
| G2 | 70 | 41 (58.6%) | 29 (41.4%) | 65 | 33 (50.8%) | 32 (49.2%) | ||
| G3 | 38 | 20 (52.6%) | 18 (47.4%) | 0.837 | 34 | 15 (44.1%) | 19 (55.9%) | |
| Chemotherapy type | 0.348 | |||||||
| Cohort A | 19 | 12 (63.2%) | 7 (36.8%) | 17 | 6 (35.3%) | 11 (64.7%) | ||
| Cohort B | 50 | 25 (50.5%) | 25 (50.0%) | 50 | 25 (50.0%) | 25 (50.0%) | ||
| Cohort C | 45 | 26 (57.8%) | 19 (36.8%) | 0.561 | 39 | 22 (56.4%) | 17 (43.6%) | |
Notes: Cohort A: patients receiving exclusively anthracycline-based chemotherapy. Cohort B: patients receiving chemotherapy, including agents other than anthracyclines (eg, taxane-based and others). Cohort C: patients receiving no chemotherapy.